Celltrion Signs $744 Million Deal for Two Preclinical Autoimmune Drug Candidates
patrickwareing.com/news/celltri...
patrickwareing.com/news/celltri...
Celltrion Signs $744 Million Deal for Two Preclinical Autoimmune Drug Candidates - Patrick Wareing
South Korean biopharmaceutical company Celltrion has expanded its pipeline beyond biosimilars by signing a licensing deal worth up to $744 million for two
patrickwareing.com
November 5, 2025 at 5:04 PM
Celltrion Signs $744 Million Deal for Two Preclinical Autoimmune Drug Candidates
patrickwareing.com/news/celltri...
patrickwareing.com/news/celltri...
Kaigene and Celltrion Forge Alliance to Develop Innovative Antibody Therapies for Autoimmune Disorders#United_States#Rockville#Celltrion#antibody_therapeutics#Kaigene
Kaigene and Celltrion Forge Alliance to Develop Innovative Antibody Therapies for Autoimmune Disorders
Kaigene has signed a licensing deal with Celltrion to develop advanced antibody therapeutics targeting autoimmune diseases, opening new avenues for treatment.
third-news.com
November 4, 2025 at 12:10 AM
Kaigene and Celltrion Forge Alliance to Develop Innovative Antibody Therapies for Autoimmune Disorders#United_States#Rockville#Celltrion#antibody_therapeutics#Kaigene
U.S. FDA Designates Celltrion's Biosimilars STOBOCLO and OSENVELT as Interchangeable Choices#USA#Incheon#Celltrion#STOBOCLO#OSENVELT
U.S. FDA Designates Celltrion's Biosimilars STOBOCLO and OSENVELT as Interchangeable Choices
The FDA has granted Celltrion's biosimilars, STOBOCLO and OSENVELT, interchangeability designations, improving treatment options for osteoporosis and cancer-related bone conditions.
third-news.com
October 30, 2025 at 7:37 AM
U.S. FDA Designates Celltrion's Biosimilars STOBOCLO and OSENVELT as Interchangeable Choices#USA#Incheon#Celltrion#STOBOCLO#OSENVELT
Regeneron Settles Litigations with Celltrion over EYLEA® Biosimilar Eydenzelt®
Regeneron Settles Litigations with Celltrion over EYLEA® Biosimilar Eydenzelt®
On October 20, 2025, Celltrion and Regeneron announced they reached a settlement agreement, dismissing Case Nos. 1-23-cv-00089 (N.D.W. Va.) and...
www.jdsupra.com
October 29, 2025 at 4:24 PM
Regeneron Settles Litigations with Celltrion over EYLEA® Biosimilar Eydenzelt®
Regeneron Settles Litigations with Celltrion over EYLEA® Biosimilar Eydenzelt®
Regeneron Settles Litigations with Celltrion over EYLEA® Biosimilar Eydenzelt®
On October 20, 2025, Celltrion and Regeneron announced they reached a settlement agreement, dismissing Case Nos. 1-23-cv-00089 (N.D.W. Va.) and...
www.jdsupra.com
October 29, 2025 at 4:24 PM
Regeneron Settles Litigations with Celltrion over EYLEA® Biosimilar Eydenzelt®
Regeneron Settles Litigations with Celltrion over EYLEA® Biosimilar Eydenzelt®
Regeneron Settles Litigations with Celltrion over EYLEA® Biosimilar Eydenzelt®
On October 20, 2025, Celltrion and Regeneron announced they reached a settlement agreement, dismissing Case Nos. 1-23-cv-00089 (N.D.W. Va.) and...
www.jdsupra.com
October 29, 2025 at 4:24 PM
Regeneron Settles Litigations with Celltrion over EYLEA® Biosimilar Eydenzelt®
Celltrion launches Actemra® Biosimilar Avtozma®
Celltrion launches Actemra® Biosimilar Avtozma®
On October 2, 2025, Celltrion launched Avtozma® (tocilizumab-anoh), in intravenous and subcutaneous formulations, as the third biosimilar...
www.jdsupra.com
October 27, 2025 at 4:53 PM
Celltrion launches Actemra® Biosimilar Avtozma®
Celltrion launches Actemra® Biosimilar Avtozma®
Celltrion launches Actemra® Biosimilar Avtozma®
On October 2, 2025, Celltrion launched Avtozma® (tocilizumab-anoh), in intravenous and subcutaneous formulations, as the third biosimilar...
www.jdsupra.com
October 27, 2025 at 4:53 PM
Celltrion launches Actemra® Biosimilar Avtozma®
Celltrion launches Actemra® Biosimilar Avtozma®
Celltrion launches Actemra® Biosimilar Avtozma®
On October 2, 2025, Celltrion launched Avtozma® (tocilizumab-anoh), in intravenous and subcutaneous formulations, as the third biosimilar...
www.jdsupra.com
October 27, 2025 at 4:53 PM
Celltrion launches Actemra® Biosimilar Avtozma®
Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026 - Fierce Pharma: Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026 Fierce Pharma
Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026 - Fierce Pharma
Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026 Fierce Pharma
news.google.com
October 22, 2025 at 12:25 PM
Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026 - Fierce Pharma: Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026 Fierce Pharma
PNBN Trending: Regeneron reaches patent deal with Celltrion over Eylea biosimilar https://zpr.io/hBBRFrNpL9Vp
October 22, 2025 at 5:09 AM
PNBN Trending: Regeneron reaches patent deal with Celltrion over Eylea biosimilar https://zpr.io/hBBRFrNpL9Vp
Regeneron's patent settlement with Celltrion paves way for another Eylea biosimilar in 2026 - Endpoints News: Regeneron's patent settlement with Celltrion paves way for another Eylea biosimilar in 2026 Endpoints News
Regeneron's patent settlement with Celltrion paves way for another Eylea biosimilar in 2026 - Endpoints News
Regeneron's patent settlement with Celltrion paves way for another Eylea biosimilar in 2026 Endpoints News
news.google.com
October 21, 2025 at 6:21 PM
Regeneron's patent settlement with Celltrion paves way for another Eylea biosimilar in 2026 - Endpoints News: Regeneron's patent settlement with Celltrion paves way for another Eylea biosimilar in 2026 Endpoints News
Regeneron and Celltrion Settle Eylea Biosimilar Patent Fight - Bloomberg Law News: Regeneron and Celltrion Settle Eylea Biosimilar Patent Fight Bloomberg Law News
Regeneron and Celltrion Settle Eylea Biosimilar Patent Fight - Bloomberg Law News
Regeneron and Celltrion Settle Eylea Biosimilar Patent Fight Bloomberg Law News
news.google.com
October 20, 2025 at 10:20 PM
Regeneron and Celltrion Settle Eylea Biosimilar Patent Fight - Bloomberg Law News: Regeneron and Celltrion Settle Eylea Biosimilar Patent Fight Bloomberg Law News
WellsCare and Celltrion Canada Join Forces to Revolutionize Pain Management Technology#South_Korea#Seoul#Celltrion#WellsCare#IASO
WellsCare and Celltrion Canada Join Forces to Revolutionize Pain Management Technology
WellsCare partners with Celltrion Canada to launch innovative pain relief technology across North America, enhancing patient care.
third-news.com
October 20, 2025 at 1:47 PM
WellsCare and Celltrion Canada Join Forces to Revolutionize Pain Management Technology#South_Korea#Seoul#Celltrion#WellsCare#IASO
The #FDA has expanded pediatric indications for adalimumab-aaty (Yuflyma; Celltrion USA) and unbranded adalimumab-aaty to include the treatment of hidradenitis suppurativa in adolescent patients aged 12 years and older, and uveitis in pediatric patients aged 2 years and older.
October 17, 2025 at 1:49 PM
The #FDA has expanded pediatric indications for adalimumab-aaty (Yuflyma; Celltrion USA) and unbranded adalimumab-aaty to include the treatment of hidradenitis suppurativa in adolescent patients aged 12 years and older, and uveitis in pediatric patients aged 2 years and older.
FDA Expands Pediatric Use of YUFLYMA® and Unbranded Adalimumab-aaty for Chronic Conditions#United_States#Incheon#Celltrion#YUFLYMA®#Adalimumab
FDA Expands Pediatric Use of YUFLYMA® and Unbranded Adalimumab-aaty for Chronic Conditions
The FDA has approved YUFLYMA® and its unbranded counterpart for new pediatric uses, enhancing treatment options for chronic inflammatory diseases in kids.
third-news.com
October 17, 2025 at 5:41 AM
FDA Expands Pediatric Use of YUFLYMA® and Unbranded Adalimumab-aaty for Chronic Conditions#United_States#Incheon#Celltrion#YUFLYMA®#Adalimumab
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
#Launch #BigMoleculeWatch
www.bigmoleculewatch.com/2025/10/13/c...
#Launch #BigMoleculeWatch
www.bigmoleculewatch.com/2025/10/13/c...
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
On October 2, 2025, Celltrion, Inc. (“Celltrion”) announced the commercial launch of AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA® in the United States.
www.bigmoleculewatch.com
October 14, 2025 at 2:57 PM
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
#Launch #BigMoleculeWatch
www.bigmoleculewatch.com/2025/10/13/c...
#Launch #BigMoleculeWatch
www.bigmoleculewatch.com/2025/10/13/c...
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
On October 2, 2025, Celltrion, Inc. (“Celltrion”) announced the commercial launch of AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA® in the...
www.jdsupra.com
October 13, 2025 at 9:28 PM
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
On October 2, 2025, Celltrion, Inc. (“Celltrion”) announced the commercial launch of AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA® in the...
www.jdsupra.com
October 13, 2025 at 9:28 PM
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
On October 2, 2025, Celltrion, Inc. (“Celltrion”) announced the commercial launch of AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA® in the...
www.jdsupra.com
October 13, 2025 at 9:28 PM
Celltrion Announces Launch of AVTOZMA® (tocilizumab-anoh) Intravenous Formulation in the United States
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
https://www.newsbeep.com/il/64640/
EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following…
https://www.newsbeep.com/il/64640/
EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following…
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept) - Israel News Beep
INCHEON, South Korea, Oct. 9, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT®
www.newsbeep.com
October 9, 2025 at 11:40 PM
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
https://www.newsbeep.com/il/64640/
EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following…
https://www.newsbeep.com/il/64640/
EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following…
Celltrion Secures FDA Approval for EYDENZELT®: A New Hope for Eye Disease Treatment#South_Korea#FDA_Approval#Incheon#Celltrion#EYDENZELT
Celltrion Secures FDA Approval for EYDENZELT®: A New Hope for Eye Disease Treatment
Celltrion proudly announces the FDA's approval of EYDENZELT®, a biosimilar to EYLEA®, enhancing treatment options for retinal diseases like AMD and DME.
third-news.com
October 9, 2025 at 11:00 PM
Celltrion Secures FDA Approval for EYDENZELT®: A New Hope for Eye Disease Treatment#South_Korea#FDA_Approval#Incheon#Celltrion#EYDENZELT
🤧 Une nouvelle avancée pour les patients asthmatiques et allergiques !
Celltrion Healthcare France annonce la mise à disposition en France d’Omlyclo, le premier biosimilaire d’omalizumab en Europe.
📲 À découvrir ici : on-health.tv/vers-un-nouv...
#innovtaion #santé #asthme #traitement
Celltrion Healthcare France annonce la mise à disposition en France d’Omlyclo, le premier biosimilaire d’omalizumab en Europe.
📲 À découvrir ici : on-health.tv/vers-un-nouv...
#innovtaion #santé #asthme #traitement
Vers un nouveau traitement de l'asthme sévère et de l'urticaire chronique ? - ON HEALTH
Celltrion Healthcare vient d'annoncer la mise à disposition en France d'un traitement innovant de l'asthme sévère et de l'urticaire chronique.
on-health.tv
October 6, 2025 at 7:28 AM
🤧 Une nouvelle avancée pour les patients asthmatiques et allergiques !
Celltrion Healthcare France annonce la mise à disposition en France d’Omlyclo, le premier biosimilaire d’omalizumab en Europe.
📲 À découvrir ici : on-health.tv/vers-un-nouv...
#innovtaion #santé #asthme #traitement
Celltrion Healthcare France annonce la mise à disposition en France d’Omlyclo, le premier biosimilaire d’omalizumab en Europe.
📲 À découvrir ici : on-health.tv/vers-un-nouv...
#innovtaion #santé #asthme #traitement